BiomeMega

BiomeMega is a South Korean biotechnology company specializing in the development of microbiome-derived functional ingredients and therapeutics. The company utilizes a proprietary microbial fermentation platform to produce high-purity, bio-available Omega-3 fatty acids and other bioactive compounds. Their primary focus is on addressing inflammatory and metabolic conditions, with a lead pipeline candidate targeting dry eye syndrome. By leveraging microbiome-based bio-conversion, BiomeMega aims to provide sustainable and highly effective alternatives to traditional animal-derived supplements and medicines. The company's technology allows for the production of vegan Omega-3s that bypass the environmental and purity issues associated with fish-derived oils.